Floatz logo

ML261

Gastroenteropancreatic NEC (GEP NEC)

Moonlight Bio, IncCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Gastroenteropancreatic NEC (GEP NEC) cohort.

Asset / SponsorPhaseRating
[212pb]pb-mp0712
Molecular Partners AG
Phase 1/2CCC
[203Pb]Pb-MP0712
Molecular Partners AG
Phase 1/2CCC

Same molecule, other indications

ML261 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Dormant
CC
Indicative ·
43 / 100
View asset →
prostate neuroendocrine neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →